Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
The Boomer and Gunnar Esiason Story," detailing a remarkable father-son journey of perseverance and resilience.
The US Food and Drug Administration has approved Alyftrek, a once-daily oral combination of vanzacaftor, tezacaftor, and ...
BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback